首页> 外文期刊>Neonatology >A double-blind randomised controlled trial of fish oil-based versus soy-based lipid preparations in the treatment of infants with parenteral nutrition-associated cholestasis
【24h】

A double-blind randomised controlled trial of fish oil-based versus soy-based lipid preparations in the treatment of infants with parenteral nutrition-associated cholestasis

机译:鱼油基和大豆基脂质制剂治疗肠外营养相关胆汁淤积的婴儿的双盲随机对照试验

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Infants receiving prolonged parenteral nutrition (PN) are at risk of PN-associated cholestasis (PNAC). This can progress to hepatic failure and death if PN cannot be discontinued. Fish oil-based parenteral lipid preparation (FOLP) has been shown to be beneficial in case studies. Objectives: (1) To evaluate whether FOLP could halt or reverse the progression of PNAC compared with soy-based parenteral lipid preparation (SLP) and (2) to assess the effects of FOLP on liver function and physical growth. Methods: Design: double-blind randomised controlled trial. Setting: level III neonatal intensive care unit. Participants: infants with PNAC (plasma-conjugated bilirubin concentration ≥34 μmol/l or 2 mg/dl) expected to be PN-dependent for >2 weeks. Intervention: to receive either FOLP or SLP at 1.5 g/kg/day. Primary outcome measure: reversal of PNAC within 4 months after commencement of lipid treatment; secondary outcomes: rate of change of weekly liver function tests, infant growth parameters, blood lipid profile and episodes of late-onset sepsis. Results: A total of 9 infants were randomised to the FOLP group and 7 to the SLP group. There was no significant difference in reversal of PNAC at 4 months between groups. Rates of increase of plasma-conjugated bilirubin and alanine aminotransferase in the SLP group were significantly greater than the FOLP group (13.5 vs. 0.6 μmol/l per week and 9.1 vs. 1.1 IU/l per week, respectively, p = 0.03). Increased enteral nutrition was associated with significant improvement of PNAC in infants receiving FOLP compared with SLP (-8.5 vs. -1.6 μmol/l per 10% increase in enteral nutrition, respectively). The study was terminated prematurely. Conclusions: progression of PNAC in PN-dependent infants can be halted by replacing SLP with FOLP and reversed by increasing the proportion of enteral nutrition in infants receiving FOLP. Replacement of SLP with FOLP in PN-dependent infants who develop PNAC may be considered.
机译:背景:接受长时间肠外营养(PN)的婴儿有与PN相关的胆汁淤积(PNAC)的风险。如果无法中断PN,则可能导致肝衰竭甚至死亡。基于鱼油的肠胃外脂质制剂(FOLP)已被证明在案例研究中是有益的。目的:(1)与基于大豆的肠胃外脂质制剂(SLP)相比,评估FOLP是否可以阻止或逆转PNAC的进展;(2)评估FOLP对肝功能和身体生长的影响。方法:设计:双盲随机对照试验。地点:三级新生儿重症监护室。参与者:PNAC(血浆结合胆红素浓度≥34μmol/ l或2 mg / dl)的婴儿预期PN依赖性> 2周。干预:以1.5 g / kg /天的剂量接受FOLP或SLP。主要结果指标:脂质治疗开始后4个月内PNAC逆转;次要结果:每周肝功能测试的变化率,婴儿生长参数,血脂谱和迟发性败血症的发作。结果:共有9例婴儿随机分为FOLP组和7例SLP组。两组之间PNAC的逆转在4个月时没有显着差异。 SLP组血浆结合胆红素和丙氨酸转氨酶的增加率显着高于FOLP组(分别为每周13.5 vs. 0.6μmol/ l和每周9.1 vs. 1.1 IU / l,p = 0.03)。与SLP相比,接受FOLP的婴儿肠内营养的增加与PNAC的显着改善有关(每增加10%的肠内营养,分别为-8.5和-1.6μmol/ l)。该研究提前终止。结论:用FOLP代替SLP可以阻止PN依赖型婴儿PNAC的发展,而通过增加FOLP婴儿的肠内营养比例可以逆转PNAC的进展。在发展为PNAC的PN依赖型婴儿中,可以考虑用FOLP替代SLP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号